{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:14:11Z","timestamp":1789910051913,"version":"4.0.1"},"reference-count":21,"publisher":"European Respiratory Society (ERS)","issue":"139","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2015,11,22]]},"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>Multidrug-resistant (MDR) tuberculosis (TB) is a threat to global TB control, as suboptimal and poorly tolerated treatment options have resulted in largely unfavourable outcomes for these patients. The last of six cohort studies conducted in Bangladesh which assessed a new shorter regimen using currently available TB drugs showed promising results and offered the possibility of a more acceptable and more effective regimen than the one recommended by the World Health Organization (WHO). The aims of stage 1 of the STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) trial are to evaluate the efficacy and safety of this regimen, compared to the current WHO-recommended standard of care. Stage 2 evaluates two new bedaquiline-containing regimens: one an all-oral regimen and the second a further shortened and simplified version of the stage 1 study regimen, comparing the efficacy and safety of each to that of the stage 1 study regimen and also to the WHO-recommended standard of care. Success of the stage 1 study regimen would in all probability provide a new standard of care for MDR-TB patients, while positive results from the bedaquiline-containing regimens in stage 2 may allow for even greater progress in the management of this difficult population.<\/jats:p>","DOI":"10.1183\/16000617.0080-2015","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T01:57:47Z","timestamp":1456797467000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials"],"prefix":"10.1183","volume":"25","author":[{"given":"Riya","family":"Moodley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Godec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"2024102403194504000_25.139.29.1","unstructured":"World Health Organization. Global Tuberculosis Report 2015. Geneva, World Health Organization, 2015."},{"key":"2024102403194504000_25.139.29.2","unstructured":"World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: 2011 Update. Geneva, World Health Organization, 2011."},{"key":"2024102403194504000_25.139.29.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073611"},{"key":"2024102403194504000_25.139.29.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2024102403194504000_25.139.29.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.021"},{"key":"2024102403194504000_25.139.29.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079413"},{"key":"2024102403194504000_25.139.29.7","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100"},{"key":"2024102403194504000_25.139.29.8","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0535"},{"key":"2024102403194504000_25.139.29.9","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"2024102403194504000_25.139.29.10","first-page":"S15","article-title":"Expanding shortened MDR-TB treatment: the West African experience","volume":"18: Suppl. 1","author":"Tr\u00e9bucq","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403194504000_25.139.29.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300"},{"key":"2024102403194504000_25.139.29.12","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-353"},{"key":"2024102403194504000_25.139.29.13","unstructured":"National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. www.niaid.nih.gov\/labsandresources\/resources\/daidsclinrsrch\/documents\/daidsaegradingtable.pdf Date last updated: December, 2004."},{"key":"2024102403194504000_25.139.29.14","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403194504000_25.139.29.15","unstructured":"Food and Drug Administration. Determination That TEQLUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness. www.fda.gov\/OHRMS\/DOCKETS\/98fr\/cd07129-n.pdf Date last updated: September 9, 2008."},{"key":"2024102403194504000_25.139.29.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314385"},{"key":"2024102403194504000_25.139.29.17","doi-asserted-by":"publisher","DOI":"10.4103\/2229-516X.112228"},{"key":"2024102403194504000_25.139.29.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00122313"},{"key":"2024102403194504000_25.139.29.19","unstructured":"World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-resistant Tuberculosis: Interim Policy Guidance. http:\/\/apps.who.int\/iris\/bitstream\/10665\/84879\/1\/9789241505482_eng.pdf Date last accessed: October 18, 2015. Date last updated: June 2013."},{"key":"2024102403194504000_25.139.29.20","first-page":"241","article-title":"Timing of relapse in short-course chemotherapy trials for tuberculosis","volume":"14","author":"Nunn","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102403194504000_25.139.29.21","unstructured":"World Health Organization. Resistance to Pyrazinamide and Fluoroquinolones: Results from a Multi-country Surveillance Project. Proceedings of the 45th Union World Conference on Lung Health; October 28\u2013November 1, 2014; Barcelona, Spain. www.who.int\/tb\/advisory_bodies\/impact_measurement_taskforce\/meetings\/barcelona2014_zignol.pdf Date last accessed: October 22, 2015. Date last updated: October 2014."}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0080-2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:58:24Z","timestamp":1740373104000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0080-2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":21,"journal-issue":{"issue":"139","published-online":{"date-parts":[[2016,2,29]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1183\/16000617.0080-2015"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0080-2015","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}